Published in Toxicol Appl Pharmacol on December 01, 1979
Two-generation saccharin bioassays. Environ Health Perspect (1983) 0.75
Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. A 31P nuclear magnetic resonance study. Lancet (1984) 4.42
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol (2001) 2.75
Phylogeny of the genus Pseudomonas: intrageneric structure reconstructed from the nucleotide sequences of gyrB and rpoD genes. Microbiology (2000) 2.73
Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy. Ann Neurol (1999) 2.67
Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region. Brain (2003) 2.57
Identification of a pathogenicity island, which contains genes for virulence and avirulence, on a large native plasmid in the bean pathogen Pseudomonas syringae pathovar phaseolicola. Proc Natl Acad Sci U S A (1999) 2.39
Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR. Magn Reson Med (1984) 2.21
Surgical outcome in patients with epilepsy and dual pathology. Brain (1999) 2.19
Safety evaluation and risk assessment of the herbicide Roundup and its active ingredient, glyphosate, for humans. Regul Toxicol Pharmacol (2000) 1.97
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol (2000) 1.92
Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med (1995) 1.92
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 1.71
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med (1996) 1.71
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain (1998) 1.68
Incidence of acquired demyelination of the CNS in Canadian children. Neurology (2009) 1.63
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain (1999) 1.56
Toxicological consequences of aroclor 1254 ingestion by female rhesus (Macaca mulatta) monkeys. Part 2. Reproduction and infant findings. Food Chem Toxicol (1995) 1.55
Is ictal recording mandatory in temporal lobe epilepsy? Not when the interictal electroencephalogram and hippocampal atrophy coincide. Arch Neurol (2000) 1.52
Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2006) 1.46
Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images. Ann Neurol (1994) 1.35
A validation study of multicenter diffusion tensor imaging: reliability of fractional anisotropy and diffusivity values. AJNR Am J Neuroradiol (2011) 1.32
Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol (2000) 1.31
Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol (1985) 1.29
Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy. Ann Neurol (2001) 1.29
Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport (1998) 1.27
Magnetic resonance spectroscopy and imaging of the thalamus in idiopathic generalized epilepsy. Brain (2003) 1.24
Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol (1999) 1.24
Metabolism of inorganic arsenic (74As) in humans following oral ingestion. Toxicol Appl Pharmacol (1979) 1.23
Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol (2001) 1.23
Reliability, validity, and applicability of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) for adults with multiple sclerosis. Disabil Rehabil (2002) 1.22
Entorhinal cortex atrophy in epilepsy patients exhibiting normal hippocampal volumes. Neurology (2001) 1.22
Separation of arsenic metabolites in dog plasma and urine following intravenous injection of 74As. Anal Biochem (1978) 1.22
Regional variations in normal brain shown by quantitative magnetization transfer imaging. Magn Reson Med (2004) 1.21
Chronic effects of ingested asbestos in rats. Arch Environ Contam Toxicol (1977) 1.21
Pesticide acute toxicity reference values for birds. Rev Environ Contam Toxicol (2001) 1.20
T2 relaxometry can lateralize mesial temporal lobe epilepsy in patients with normal MRI. Neuroimage (2000) 1.19
Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology (1994) 1.18
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
Human retention studies with 74As. Toxicol Appl Pharmacol (1980) 1.17
Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology (1997) 1.17
In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain (1999) 1.17
Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain (2000) 1.16
Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage (2007) 1.16
Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol (1997) 1.15
Frequency and characteristics of dual pathology in patients with lesional epilepsy. Neurology (1995) 1.14
Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol (1997) 1.13
Mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal. Ann Neurol (1996) 1.13
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler (2008) 1.13
A proton magnetic resonance spectroscopy study of focal epilepsy in humans. Neurology (1990) 1.13
Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage (2004) 1.12
Acute toxicity studies on roquefortine and PR toxin, metabolites of Penicillium roqueforti, in the mouse. Food Cosmet Toxicol (1978) 1.11
Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve (2000) 1.10
Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination. Neurology (2011) 1.10
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol (1998) 1.08
Naturally occurring toxicants in foods and their significance. Clin Toxicol (1976) 1.08
Regional brain atrophy in children with multiple sclerosis. Neuroimage (2011) 1.07
Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg (1997) 1.07
Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. Pediatr Neurol (1994) 1.07
Evaluation of certain food additives and contaminants. World Health Organ Tech Rep Ser (2007) 1.06
Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol (2002) 1.06
Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. Brain (2002) 1.05
Magnetic resonance imaging shows specific abnormalities in the MELAS syndrome. Neurology (1991) 1.04
Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol (1995) 1.04
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology (2006) 1.04
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology (2007) 1.04
Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology (1993) 1.03
Ethoxyresorufin-O-deethylase and porphyrin analysis in chicken embryo hepatocyte cultures with a fluorescence multiwell plate reader. Anal Biochem (1993) 1.03
MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology (2011) 1.02
Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology (1991) 1.02
Morphometric MRI analysis of the parahippocampal region in temporal lobe epilepsy. Ann N Y Acad Sci (2000) 1.01
Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Ann Neurol (2000) 1.01
Chronic toxicity of methylmercury in the adult cat. Interim report. Toxicology (1976) 1.01
Erythritol: a review of biological and toxicological studies. Regul Toxicol Pharmacol (1996) 1.00
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol (2006) 0.97
In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology (1991) 0.97
The FEMA GRAS assessment of pyrazine derivatives used as flavor ingredients. Flavor and Extract Manufacturers Association. Food Chem Toxicol (2002) 0.96
Report of an Expert Panel on the reanalysis by of a 90-day study conducted by Monsanto in support of the safety of a genetically modified corn variety (MON 863). Food Chem Toxicol (2007) 0.96
Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia (2001) 0.96
Ochratoxin A--occurrence and toxicity. J Am Vet Med Assoc (1973) 0.96
Eccrine adenocarcinoma of the eyelid in a young patient. Ophthal Plast Reconstr Surg (1993) 0.95
Relating axonal injury to functional recovery in MS. Neurology (2000) 0.95
Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology (2000) 0.95
Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology (1995) 0.94
Effects of PCB (Aroclor 1254) on non-specific immune parameters in rhesus (Macaca mulatta) monkeys. Int J Immunopharmacol (1991) 0.94
Excision from tRNA genes of a large chromosomal region, carrying avrPphB, associated with race change in the bean pathogen, Pseudomonas syringae pv. phaseolicola. Mol Microbiol (2000) 0.94
Long-term toxicity of hexachlorobenzene in the rat and the effect of dietary vitamin A. Food Chem Toxicol (1985) 0.93
The FEMA GRAS assessment of alicyclic substances used as flavour ingredients. Food Chem Toxicol (1996) 0.93
Arsenic excretion by monkeys dosed with arsenic-containing fish or with inorganic arsenic. Bull Environ Contam Toxicol (1978) 0.92
Spatial extent of neuronal metabolic dysfunction measured by proton MR spectroscopic imaging in patients with localization-related epilepsy. Epilepsia (2000) 0.92
Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain (1996) 0.92
Significance of mesial temporal atrophy in relation to intracranial ictal and interictal stereo EEG abnormalities. Brain (1996) 0.92
Prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy. Ann Neurol (2000) 0.92